Bristol just announced successful Phase IIb results for their subcutaneous injectable Clazakizumab, as a treatment for RA. Taken with methotrexate, it shows 20% improvement in patient symptoms over methotrexate alone. In that respect, it's similar to Humira from AbbVie, which is available as a pen-injection self-administration treatment.
This space for alternatives to oral methotrexate alone is getting very crowded. Anyone know what the pricing advantage or other advantage (or disadvantage) Otrexup would have in comparison these alternative subcutaneous RA treatments?
All patients are first put on MTX so we have access to 100% of the market opportunity before they go on a more expensive biologic. Once their on a biologic then we still can capture a portion of this market since the biologics show better efficacy when used in combination with MTX.
None of these new drugs should impact Otrexup's opportunity. In addition, none of these biologics are compared to SQ MTX its always vs oral MTX.